Join the Pegcetacoplan group to help and get support from people like you.
Pegcetacoplan News
FDA Approves Apellis’ Empaveli (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) – Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved Empaveli (pegcetacoplan) ...
Apellis Announces U.S. FDA Approval of the Empaveli Injector, a Device to Streamline Self-Administration
WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) – Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved the Empaveli® Injector. ...
FDA Approves Syfovre (pegcetacoplan injection) for the Treatment of Geographic Atrophy, a Leading Cause of Blindness
WALTHAM, Mass., Feb. 17, 2023 (GLOBE NEWSWIRE) – Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the U.S. Food and...
FDA Approves Empaveli (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
WALTHAM, Mass., May 14, 2021 (GLOBE NEWSWIRE) – Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the U.S....